OncLive | Six Targeted Agents for CLL Command Spotlight at ASH OncLive Brown also expressed excitement about idelalisib, a first-in-class PI3K-delta inhibitor that—in combination with rituximab— sparked a >70% improvement in OS in patients with high-risk relapsed/refractory CLL; IPI-145, an inhibitor of PI3K-delta and ... |
